http://orcid.org/0000-0002-3352-8480
References
- Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20:190–198.
- Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163–179.
- Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32.
- Guariglia R, Martorelli MC, Lerose R, et al. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016;10:1–8.
- Koinis F, Nintos G, Georgoulias V, et al. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. Expert Opin Pharmacother. 2015;16:1505–1519.
- Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525–545.
- European Medicine Agency (EMA). European public assessment report: Lonquex 2013 [cited 2018 July 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002556/WC500148383.pdf
- Summary of Product Characteristics: Lonquex: Teva Pharma B.V.; [cited 2018 July 18]. Available from: https://www.medicines.org.uk/emc/product/5422/smpc#INDICATIONS
- Summary of Product Characteristics: Neulasta: Amgen Ltd; [cited 2018 July 18]. Available from: https://www.medicines.org.uk/emc/product/6770
- Summary of Product Characteristics: Neupogen: Amgen Ltd; [cited 2018 July 18]. Available from: https://www.medicines.org.uk/emc/product/608/smpc#INDICATIONS
- Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008;42:277–288.
- Saloustros E, Tryfonidis K, Georgoulias V. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opin Pharmacother. 2011;12:851–863.
- Cortes de Miguel S, Calleja-Hernandez MA, Menjon-Beltran S, et al. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Support Care Cancer. 2015;23:547–559.
- Silvestris N, Del Re M, Azzariti A, et al. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets. 2012;16:S111–S117.
- European Medicine Agency (EMA). Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Lonquex. 30 May 2013 [cited 2018 July 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002556/WC500148382.pdf
- Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12.
- Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46.
- McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276–282.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
- Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. JCO. 2013;31:1134–1139.
- Eaton AA, Sima CS, Panageas KS. Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-medicare data. J Natl Compr Canc Netw. 2016;14:57–65.
- Morris J. The use of observational health-care data to identify and report on off-label use of biopharmaceutical products. Clin Pharmacol Ther. 2012;91:937–942.
- Nordic MDS Group. Guidelines for the diagnosis and treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia, 8th update, May 2017 2017 [cited 2018 September 4]. Available from: https://www.nmds.org/attachments/article/92/Guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20MDS%20and%20CMML_17.pdf
- Murff HJ, Patel VL, Hripcsak G, et al. Detecting adverse events for patient safety research: a review of current methodologies. J Biomed Informatics. 2003;36:131–143.
- Gavrielov-Yusim N, Bidollari I, Kaplan S, et al. Challenges of post-authorization safety studies: lessons learned and results of a French study of fentanyl buccal tablet. Pharmacoepidemiol Drug Saf. 2018;27:457–463.
- Waller PC, Wood SM, Langman MJ, et al. Review of company postmarketing surveillance studies. BMJ. 1992;304:1470–1472.